Company Profile

Industry Sector: Cardiovascular research and development with an emphasis on women’s cardiovascular health

Company Overview: Dimera is a ten-year-old privately held research and development company specializing in cardiovascular and smooth muscle drug development through a strategy based on gene expression

Target Market(s): We estimate that the market for safe, effective, low-dose, transdermal progesterone prescriptions to prevent refractory angina pectoris in the approximately 3.2 million U.S. women with atypical (nonocclusive) coronary artery dysfunction is a new, unrecognized multibillion-dollar-per-year opportunity.

Key Value Drivers

Technology*: Advanced drug delivery with transdermal progesterone cream for angina pectoris, specifically tailored to unmet needs of menopausal women. Two unique label claims are expected. The drug development platform is based on smooth muscle physiologic constriction response regulation through modulation of gene expression and receptor expression. Key regulatory targets are genes expressing hormone and eicosanoid receptors and ancillary proteins.

Competitive Advantage: 1) Gene-expression approach, specifically lack of side-effects evident in anticipated label claims. 2) Intellectual property protection of transdermal delivery route and drug mechanism of action that is optimized for the cardiovascular system.

Plan & Strategy: Ready to begin Phase III randomized, controlled trials with FDA SPA that defines the anticipated 12-18 month process to reach the remaining clinical trial data leading to marketing approval. Planned unique label claims for non-exercise induced angina (to be first on the market) and night time awakenings due to angina.

Product Development

1. Further indications for transdermal progesterone include
   a. Peripheral vascular disease,
   b. Raynaud’s disease,
   c. And a significant opportunity for established off-label uses

2. Novel approach to refractory asthma
   a. Based on control of smooth muscle reactivity
   b. Using a new, naturally occurring lead compound

3. Novel approach to urinary incontinence
   a. Currently in preclinical (cell culture) development

Management

Leadership:
R. Kent Hermsmeyer, PhD, President and CEO
Theresa L. Thompson, PhD, Research Director

Scientific Advisory Board:
Raymond Lipicky, MD (Former head of Cardio-Renal Division, FDA)
Robert Wolters, PhD (Former CMC staff of Cardio-Renal, FDA)